Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.E5.15 million granted to fund preclinical development and phase I and II clinicla trial studies for the vaccine
Subscribe to our email newsletter
Novartis has announced that the Novartis Vaccines Institute for Global Health has been awarded a grant from the Wellcome Trust to develop a bivalent vaccine for typhoid fever.
The E5.15 million grant will fund preclinical development and phase I and II studies for a vaccine that protects against both S. Typhi and S. Paratyphi A. The currently available vaccines for S. Typhi do not protect infants and young children. S. Paratyphi A is a growing problem causing 25-50% of all typhoid cases.
Dr. Daniel Vasella, Chairman and CEO of Novartis, said: The bivalent vaccine being developed by NVGH will use a novel approach to increase efficacy and address the needs of patients that other vaccines have not. This will ultimately have the potential to eradicate this disease.